The Effects of Once-Weekly Dulaglutide and Insulin Glargine on Glucose Fluctuation in Poorly Oral-Antidiabetic Controlled Patients with Type 2 Diabetes Mellitus

The Effects of Once-Weekly Dulaglutide and Insulin Glargine on Glucose Fluctuation in Poorly Oral-Antidiabetic Controlled Patients with Type 2 Diabetes Mellitus

Aim. To compare the effects of once-weekly Dulaglutide with once-daily glargine in poorly oral-antidiabetic controlled patients with type 2 diabetes mellitus (T2DM). Method. A total of 25 patients with T2DM admitted into Department of Endocrinology from December 2012 to August 2013 were randomly ass...

Full description

Bibliographic Details
Main Authors:	Jie Wang, Hui-qin Li, Xiao-hua Xu, Xiao-cen Kong, Rui Sun, Ting Jing, Lei Ye, Xiao-fei Su, Jian-hua Ma
Format:	Article
Language:	English
Published:	Hindawi Limited 2019-01-01
Series:	BioMed Research International
Online Access:	http://dx.doi.org/10.1155/2019/2682657

Similar Items

A Randomized Study to Compare the Effects of Once-Weekly Dulaglutide Injection and Once-Daily Glimepiride on Glucose Fluctuation of Type 2 Diabetes Mellitus Patients: A 26-Week Follow-Up
by: Huiqin Li, et al.
Published: (2019-01-01)

Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: comparisons with liraglutide, insulin glargine, and placebo in two randomized studies
by: Shuichi Suzuki, et al.
Published: (2017-06-01)

Efficacy and safety of dulaglutide: a novel once-weekly glucagon-like peptide-1 analogue
by: A. S. Pogorelova, et al.
Published: (2018-03-01)

Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data
by: Kugler AJ, et al.
Published: (2018-05-01)

Clinical Effectiveness and Safety of Once-Weekly GLP-1 Receptor Agonist Dulaglutide as Add-On to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes
by: Maria Mirabelli, et al.
Published: (2021-03-01)

Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses
by: Ildiko Lingvay, et al.
Published: (2020-11-01)

Initiation of insulin glargine plus oral antidiabetic drugs in patients with type 2 diabetes uncontrolled on premixed insulin
by: Ghaida Kaddaha
Published: (2017-01-01)

On the safety of insulin Glargine
by: Ivan Ivanovich Dedov, et al.
Published: (2009-09-01)

Pharmacoeconomic comparison of insulin glargine and insulin detemir in diabetes mellitus type 2
by: I. N. Dyakov, et al.
Published: (2020-05-01)

Once-weekly administration of dulaglutide, a glucagon-like peptide-1 receptor agonist, as monotherapy and combination therapy: review of the AWARD studies
by: Marina V. Shestakova, et al.
Published: (2017-08-01)

Switching From Daily DPP-4 Inhibitor to Once-Weekly GLP-1 Receptor Activator Dulaglutide Significantly Ameliorates Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes Mellitus: A Retrospective Observational Study
by: Junpei Sanada, et al.
Published: (2021-08-01)

Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naïve Patients with Type 2 Diabetes: A Randomized Controlled Trial.
by: Ajay Kumar, et al.
Published: (2016-01-01)

Efficacy and safety of dulaglutide in patients with absolute insulin deficiency
by: Kutoh Eiji, et al.
Published: (2019-07-01)

Once weekly dulaglutide therapy in type 2 diabetic subjects, real-world evidence from a tertiary care diabetes center in India
by: Jasjeet S Wasir, et al.
Published: (2018-01-01)

Achieving the composite end‐point of glycated hemoglobin <7.0% without weight gain or hypoglycemia with once‐weekly dulaglutide in Chinese patients with type 2 diabetes: A post‐hoc analysis
by: Xinhua Xiao, et al.
Published: (2020-05-01)

Conversion from insulin glargine U-100 to insulin glargine U-300 or insulin degludec and the impact on dosage requirements
by: Scott M. Pearson, et al.
Published: (2018-04-01)

Switching from glargine+insulin aspart to glargine+insulin aspart 30 before breakfast combined with exercise after dinner and dividing meals for the treatment of type 2 diabetes patients with poor glucose control – a prospective cohort study
by: Jing Li, et al.
Published: (2018-10-01)

Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes
by: Tarigan TJE, et al.
Published: (2021-01-01)

Insulin glargine: A long acting insulin analog
by: Chakkarwar P, et al.
Published: (2005-01-01)

Insulin Glargine and Insulin Aspart Overdose With Pharmacokinetic Analysis
by: Christian C.K. Kim, MD, et al.
Published: (2016-01-01)

Lantus (Insulin Glargin): new insulin on Russian market
by: Editorial team Diabetes Mellitus
Published: (2003-03-01)

The economic prognosis of the new analog of insulin glargine usage in diabetes mellitus type 2
by: D. Yu. Belousov, et al.
Published: (2018-05-01)

Economic evaluation of the fixed combination of insulin glargine and lixisenatide in Diabetes Mellitus type 2
by: S. V. Nedogoda, et al.
Published: (2020-01-01)

A population‐adjusted indirect comparison of cardiovascular benefits of once‐weekly subcutaneous semaglutide and dulaglutide in the treatment of patients with type 2 diabetes, with or without established cardiovascular disease
by: Lyndon Marc Evans, et al.
Published: (2021-07-01)

Addition of Dulaglutide for a High-Dose Insulin Requiring Patient with Type 2 Diabetes Mellitus: A Remarkable Response
by: Mehrunissa Kazim, MD, et al.
Published: (2019-03-01)

Influence of Acarbose on Plasma Glucose Fluctuations in Insulin-Treated Patients with Type 2 Diabetes: A Pilot Study
by: Feng-fei Li, et al.
Published: (2015-01-01)

Comparison of a Multiple Daily Insulin Injection Regimen (Glargine or Detemir Once Daily Plus Prandial Insulin Aspart) and Continuous Subcutaneous Insulin Infusion (Aspart) in Short-Term Intensive Insulin Therapy for Poorly Controlled Type 2 Diabetes Patients
by: Wen-shan Lv, et al.
Published: (2013-01-01)

Pragmatic Pharmacological and Economic Analysis of Insulin Glargin Use in Type 2 Diabetes Mellitus in Ukraine
by: N.V. Bezdetko, et al.
Published: (2014-04-01)

Association of Insulin Glargine Treatment with Bone Mineral Density in Patients with Type 2 Diabetes Mellitus
by: Liu D, et al.
Published: (2021-04-01)

Two-way crossover comparison of insulin glargine and insulin detemir in basal-bolus therapy using continuous glucose monitoring
by: Abe S, et al.
Published: (2011-07-01)

Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus
by: Lau IT, et al.
Published: (2017-06-01)

Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine
by: Christian Ott, et al.
Published: (2021-09-01)

Long-term insulin glargine therapy in type 2 diabetes mellitus: a focus on cardiovascular outcomes
by: Joseph JJ, et al.
Published: (2015-01-01)

Successful Insulin Glargine Treatment in Two Pet Guinea Pigs with Suspected Type 1 Diabetes Mellitus
by: Theresa Kreilmeier-Berger, et al.
Published: (2021-04-01)

Insulin glargine: pharmacokinetic and pharmacodynamic basis of clinical effect
by: Vadim Valer'evich Klimontov, et al.
Published: (2014-10-01)

Real-world outcomes of initiating insulin glargine-based treatment versus premixed analog insulins among US patients with type 2 diabetes failing oral antidiabetic drugs
by: Baser O, et al.
Published: (2013-10-01)

Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once?
by: Matteo Tacelli, et al.
Published: (2018-11-01)

Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria
by: Monika Russel-Szymczyk, et al.
Published: (2019-12-01)

Dulaglutide improves glucocorticoid-induced hyperglycemia in inpatient care and reduces dose and injection frequency of insulin
by: Hiroyuki Uchinuma, et al.
Published: (2020-05-01)

Glargine and degludec: Solution behaviour of higher dose synthetic insulins
by: Gary G. Adams, et al.
Published: (2017-08-01)